

PATIENT INFORMAT	0

SPECIMEN DETAILS

 SPECIMEN TYPE:
 Buccal Swab

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 8/26/2019

PROVIDER INFORMATION

```
Dr. Bauer
123456789
```

Pharmacogenetic Gastroenterology Report

Current Patient Medications

Zofran, Prevacid, Lexapro, Citalopram, Xanax

X)	Citalopram Insufficient Response to Citalopram (CYP2C19: Rapid Metabolizer)						
	Celexa®		sider an alternative	im plasma concentrations levels are expected medication. If citalopram is warranted, consid I response and tolerability.			
3	Lexapro	Insufficient Response to E	scitalopram (CYP	2C19: Rapid Metabolizer)	ACTIONABLE		
	Escitalopram	result in a loss of efficacy. Con	sider an alternative	oram plasma concentrations levels are expec medication. If escitalopram is warranted, cor inical response and tolerability.	-		
<u>N</u>	Prevacid	Insufficient Response to L	Insufficient Response to Lansoprazole (CYP2C19: Rapid Metabolizer)				
 Lansoprazole Helicobacter pylori eradication: increase dose by 200% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 200%. 					oonse.		
Vanax Normal Response to Alprazolam					INFORMATIVE		
	Alprazolam	Pharmacogenetic guidance: Alprazolam is primarily eliminated by metabolism via CYP3A4 and CYP3A5. Genetic polymorphisms of these genes are not expected to affect the efficacy or safety profiles of this drug. Polypharmacy guidance: The concomitant use of alprazolam with CYP3A4 inhibitors may result in increased alprazolam levels and prolonged sedation. Impairment of motor skills are also observed with some combinations. Monitor patients for exaggerated sedative effects. If possible, alprazolam should be avoided in patients receiving strong inhibitors of CYP3/ such as ketoconazole, itraconazole and ritonavir. Drugs that induce CYP3A enzymes may decrease alprazolam levels, which results in a loss of efficacy.					
1	Zofran Ondansetron	•	Normal Response to Ondansetron (CYP2D6: Normal Metabolizer) ACTION Ondansetron can be prescribed at standard label-recommended dosage and administration.				
/	Zofran	Favorable Response to Sta Variant Allele Present)	andard Ondanseti	on Dosing (ABCB1: Homozygous Muta	ant - INFORMATIVE		
	Ondansetron			ow ABCB1 transporter expression. Ondanset stration.	ron can be prescribed at		
\bigotimes	toxicity or the patient h indicated condition. Guidelines exist for adju	ntially reduced efficacy, increased has an increased risk for the usting dosage, increased vigilance or	ACTIONABLE	Recommendations based upon publication pharmacogenetic expert groups, consortia (CPIC, DPWG, FDA, EMA). Recommendatior implementation in a clinical setting. Guideli knowledge arises.	or regulatory bodies are suitable for		
\wedge	the patient has a moderate risk for the indicated c The medication can be prescribed according to star regimens or the patient's risk for the indicated cor- not increased.		n. There are insufficient or contradictory findings docume INFORMATIVE impact of a given genetic polymorphism or drug intera				





Potentially Impacted Medications

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Anticancer Agents	Antifolates		Methotrexate (Trexall®)	
Gastrointestinal	Antiemetics	Aprepitant (Emend-oral®) Dolasetron (Anzemet®) Fosaprepitant (Emend-i.v®) Fosnetupitant-Palonosetron (Akynzeo-i.v®) Metoclopramide (Reglan®) Netupitant-Palonosetron (Akynzeo- oral®) Ondansetron (Zofran®, Zuplenz®) Palonosetron (Aloxi®) Rolapitant (Varubi®)		
	Proton Pump Inhibitors	Rabeprazole (Aciphex®)	Dexlansoprazole (Dexilant®, Kapidex®) Esomeprazole (Nexium®) Lansoprazole (Prevacid®) Omeprazole (Prilosec®) Pantoprazole (Protonix®)	





NAME: John Doe ACC #: BS7 **DOB:** 12/24/1800 SEX: Male

Dosing Guidance

v	Aprepitant	Normal Response to Aprepitant	ACTIONABL
	Emend-oral®	Pharmacogenetic guidance: Aprepitant undergoes extensive metabolism via N- and O-dealkylations. T are primarily catalyzed by CYP3A4 with minor involvement from CYP1A2 and CYP2C19. The drug is also by UGT1A4 and UGT1A3. No genetically guided drug selection or dosing recommendations are available Guidance: In presence of moderate and strong CYP3A4 inhibitors, a significantly increased exposure of expected which may lead to adverse reactions. These drugs should be avoided with aprepitant. Strong C can significantly decrease aprepitant exposure resulting in a loss of efficacy. These drugs should also be aprepitant. Aprepitant is a moderate (dose-dependent) inhibitor, and an inducer of CYP3A4 and an indu Some substrates of these enzymes are contraindicated with aprepitant while others should be closely me doing adjusted when coadministered with this antiemetic medication.	glucuronidated e. Polypharmacy aprepitant is YP3A4 inducers avoided with cer of CYP2C9.
<u>^</u>	Dexlansoprazole Dexilant®, Kapidex®	Insufficient Response to Dexlansoprazole (CYP2C19: Rapid Metabolizer) Dexlansoprazole is the R-enantiomer of lansoprazole.	INFORMATIV
		 Helicobacter pylori eradication: increase dose by 200% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 200%. 	
\	Dolasetron	Normal Response to Dolasetron (CYP2D6: Normal Metabolizer)	INFORMATIV
	Anzemet [®]	Dolasetron can be prescribed at standard label-recommended dosage and administration.	
<u>^</u>	Esomeprazole	Insufficient Response to Esomeprazole (CYP2C19: Rapid Metabolizer)	INFORMATIV
	Nexium [®]	 Helicobacter pylori eradication: increase dose by 50-100% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 50-100%. 	
	Fosaprepitant	Normal Response to Fosaprepitant	ACTIONABL
	Emend-i.v®	Pharmacogenetic guidance: Fosaprepitant is a prodrug of aprepitant which is rapidly converted to apr intravenous administration. Its antiemetic effects are attributable to aprepitant. Aprepitant undergoes ex- metabolism via N- and O-dealkylations. These pathways are primarily catalyzed by CYP3A4 with minor in CYP1A2 and CYP2C19. The drug is also glucuronidated by UGT1A4 and UGT1A3. No genetically guided dosing recommendations are available. Polypharmacy Guidance: In presence of moderate and strong inhibitors, a significantly increased exposure of aprepitant is expected which may lead to adverse reaction should be avoided with fosaprepitant. Strong CYP3A4 inducers can significantly decrease aprepitant exp a loss of efficacy. These drugs should also be avoided with fosaprepitant. Aprepitant is a moderate (dose inhibitor, and an inducer of CYP3A4 and an inducer of CYP2C9. Some substrates of these enzymes are co with fosaprepitant while others should be closely monitored and their doing adjusted when coadminister antiemetic medication.	Attensive hvolvement from drug selection or CYP3A4 ons. These drugs osure resulting ir e-dependent) ontraindicated
\	Fosnetupitant- Palonosetron	Normal Response to Fosnetupitant-Palonosetron (CYP2D6: Normal Metabolizer)	INFORMATIV
	Akynzeo-i.v®	<u>Fosnetupitant</u> : Fosnetupitant is converted to netupitant via metabolic hydrolysis. Netupitant is extensive three major metabolites (desmethyl, N-oxide and a hydroxy-methyl derivatives). Metabolism is mediated CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. No genetically guided drug selection or dosing r are available for this drug. Fosnetupitant can be prescribed at standard label-recommended dosage and <u>Palonosetron</u> : Palonosetron can be prescribed at standard label-recommended dosage and	d primarily by recommendation administration.
		raisinger on a second can be presented at standard laber recommended douge and daministration	011.
<u>^</u>	Lansoprazole	Insufficient Response to Lansoprazole (CYP2C19: Rapid Metabolizer)	INFORMATIV
<u>^</u>	Lansoprazole Prevacid®		



Methotrexate	Increased Risk for Methotrexate Toxicity (MTHFR: Reduced MTHFR Activity)	INFORMATIVE
Trexall®	Leukemia or lymphoma patients who are treated with methotrexate standard regimens might have an in- likelihood of treatment interruptions due to methotrexate toxicity. Monitor the patient closely for increase and adjust the dose accordingly. Other genetic and clinical factors may also influence the patient's risk for response to methotrexate treatment. Nonmalignant conditions: a limited number of studies found an a between individuals carrying the MTHFR c.665C>T variant and methotrexate-induced toxicity in rheumato patients. However, there is insufficient data to calculate dose adjustment. Monitor patient closely for increase	creased ed side effects toxicity and ssociation oid arthritis eased side
Metoclopramide	Normal Response to Metoclopramide (CYP2D6: Normal Metabolizer)	ACTIONABLE
Reglan®	Metoclopramide can be prescribed at standard label-recommended dosage and administration.	
Netupitant- Palonosetron	Normal Response to Netupitant-Palonosetron (CYP2D6: Normal Metabolizer)	INFORMATIVE
Akynzeo-oral®	derivatives). Metabolism is mediated primarily by CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. guided drug selection or dosing recommendations are available for this drug. Netupitant can be prescribe label-recommended dosage and administration.	No genetically ed at standard
Omeprazole	Insufficient Response to Omeprazole (CYP2C19: Rapid Metabolizer)	ACTIONABLE
Prilosec®	 Helicobacter pylori eradication: increase dose by 100-200% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 100-200%. 	
Ondansetron	Normal Response to Ondansetron (CYP2D6: Normal Metabolizer)	ACTIONABLE
Zofran®, Zuplenz®	Ondansetron can be prescribed at standard label-recommended dosage and administration.	
Palonosetron	Normal response to Palonosetron (CYP2D6: Normal Metabolizer)	INFORMATIVE
Aloxi®	Palonosetron can be prescribed at standard label-recommended dosage and administration.	
Pantoprazole	Insufficient Response to Pantoprazole (CYP2C19: Rapid Metabolizer)	ACTIONABLE
Protonix [®]	 Helicobacter pylori eradication: increase dose by 400% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 400%. 	
Rabeprazole	Normal Response to Rabeprazole (CYP2C19: Rapid Metabolizer)	INFORMATIVE
Aciphex®	Rabeprazole can be prescribed at standard dosage and administration.	
Rolapitant Varubi®	Normal Response to Rolapitant	ACTIONABLE
	Trexall®Metoclopramide Reglan®Netupitant- Palonosetron Akynzeo-oral®Omeprazole Prilosec®Ondansetron Zofran®, Zuplenz®Palonosetron Aloxi®Palonosetron Aloxi®Rabeprazole Protonix®Rabeprazole Aciphex®Rolapitant	Trexall® The patient carries one copy of the MTHER c655C-T variant resulting in a reduced MTHER activity. Multiple Leukemia or lymphoma patients who are treated with methotrexate toxicity, Monitor the patient closely for increase and adjust the dose accordingly. Other genetic and clinical factors may also influence the patients in known from the conditions: a linute down of the single conditions and the dose accordingly. Other genetic and clinical factors may also influence the patient site with the single conditions at linute down and extense to methotrexate treatment. Monitor patient closely for increase and adjust the dose accordingly. Other genetic and clinical factors may also influence the patient's and response to methotrexate treatment. Metoclopramide Region® Normal Response to Metoclopramide (CYP2D6: Normal Metabolizer) Metoclopramide regions by the total solution of the single conditions and the single conditions and the dose accordingly. Other genetic and clinical factors may also influence the patient's and response to methotrexate treatment. Normal Response to Metoclopramide (CYP2D6: Normal Metabolizer) Metoclopramide can be prescribed at standard label-recommended dosage and administration. Netupitant: Netupitant is extensively metabolized to three major metabolites (desmethyl. N-oxide and a label-recommended dosage and administration. Determine an immunistration and the prescribed at standard label-recommended dosage and administration. Palonosetron Insufficient Response to Omeprazole (CYP2C19: Rapid Metabolizer) Other be extra alert to insufficient response. Ondansetron Normal Response to Ondansetron (CYP2D6: Normal Metabolizer) Other: be extra al



PATIENT INFORMATION

 NAME:
 John Doe

 ACC #:
 BS7

 DOB:
 12/24/1800

 SEX:
 Male

Pharmacogenetic guidance: Rolapitant is metabolized primarily by CYP3A4 to a major active metabolite, (C4pyrrolidinehydroxylated rolapitant). Rolapitant is eliminated primarily through the hepatic/biliary route. No genetically guided drug selection or dosing recommendations are available. **Polypharmacy Guidance:** Strong CYP3A4 inducers can significantly decrease rolapitant exposure resulting in a loss of efficacy. These drugs should be avoided with rolapitant. Rolapitant is a moderate CYP2D6 inhibitor and some CYP2D6 substrates (e.g. thioridazine, pimozide) are contraindicated with rolapitant while others should be closely monitored and their doing adjusted when coadministered with this antiemetic medication. Rolapitant is an inhibitor two major drug efflux transporters: breast-cancer-resistance protein (BCRP) and Pglycoprotein (P-gp). Increased plasma concentrations of BCRP or P-gp substrates may result in potential adverse reactions when coadministered with rolapitant.





Test Details

Gene	Genotype	Phenotype	Clinical Consequences
CYP2C19	*1/*17	Rapid Metabolizer	Consistent with a significant increase in CYP2C19 activity. Potential risk for side effects or loss of efficacy with drug substrates.
CYP2D6	*1/*5	Normal Metabolizer	Consistent with a typical CYP2D6 activity. This test did not identify risks for side effects or loss of efficacy with drug substrates.
СҮРЗА4	*1/*1	Normal Metabolizer	Consistent with a typical CYP3A4 activity. Caution is advised when prescribing narrow therapeutic index drugs. Alternative drugs or dose adjustment may be required if CYP3A inhibitors or inducers are co-prescribed.

Alleles Tested: CYP2C19 *2, *3, *4, *4B, *5, *6, *7, *8, *9, *10, *13, *17; CYP2D6 *2, *3, *4, *4M, *6, *7, *8, *9, *10, *11, *12, *15, *17, *29, *35, *41, *5 (gene deletion), XN (gene duplication); CYP3A4 *1B, *3, *6, *8, *11, *12, *13, *15, *16A, *16B, *17, *18A, *18B, *22; MTHFR c.665C>T, c.1286A>C

Limitation: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits. Technical limitations include the possibility of laboratory error and inaccuracy of the test due to unknown rare variants.

Methodology: Bead array and e-sensor based assays detect listed alleles and most rare variants with known clinical significance and analytical sensitivity and specificity >99%.

Lab Disclaimer: Genesys Diagnostics Inc. has validated the Genotype Test. The performance characteristics of this test were determined by Genesys Diagnostics Inc. This test is an FDA modified and Lab Developed Test.

Translational Software Disclaimer: The information presented on this report is provided as general educational health information. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Only a physician, pharmacist or other healthcare professional should advise a patient on the use of the medications prescribed.

The pharmacogenetic assay involves use of reporting software and genotype-phenotype associations performed by Translational Software (www.translationalsoftware.com). The software has not been evaluated by the Food and Drug Administration. The software, and the report generated by the software, is not intended to diagnose, treat, cure, or prevent any disease. A qualified designee within the lab uses Translational Software to generate and subsequently review the report. The pharmacogenetic report is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to dose guidelines does not necessarily assure a successful medical outcome.

Report was signed out electronically by on //.





ΑΤΙ	ENT	INF	ORM	IATI	10

SPECIMEN DETAILS

COLLECTION DATE: 1/1/1900

SPECIMEN TYPE:

RECEIVED DATE:

REPORT DATE:

ORDERED BY

Dr. Bauer

Buccal Swab

1/1/1900 8/26/2019

Comprehensive Pharmacogenetic Report with DDI

Current Patient Medications

Zofran, Prevacid, Lexapro, Citalopram, Xanax

§ 🛞	Citalopram Celexa®	Insufficient Response to Citalopram (CYP2C19: Rapid Metabolizer) At standard label-recommended dosage, citalopram plasma concentrations levels are expected to be	ACTIONABLE low which may
		result in a loss of efficacy. Consider an alternative medication. If citalopram is warranted, consider incredent dose to a maximum of 150% and titrate based on the clinical response and tolerability.	easing the
§ 🚫	Lexapro	Insufficient Response to Escitalopram (CYP2C19: Rapid Metabolizer)	ACTIONABLE
	Escitalopram	At standard label-recommended dosage, escitalopram plasma concentrations levels are expected to b may result in a loss of efficacy. Consider an alternative medication. If escitalopram is warranted, consider the dose to a maximum of 150% and titrate based on the clinical response and tolerability.	
ð 🔨	Prevacid Lansoprazole	 Insufficient Response to Lansoprazole (CYP2C19: Rapid Metabolizer) Helicobacter pylori eradication: increase dose by 200% and be alert to insufficient response. Other: be extra alert to insufficient response and consider dose increase of 200%. 	INFORMATIVE
₹√	Xanax	Normal Response to Alprazolam	INFORMATIVE
	Alprazolam	Pharmacogenetic guidance: Alprazolam is primarily eliminated by metabolism via CYP3A4 and CYP3 polymorphisms of these genes are not expected to affect the efficacy or safety profiles of this drug. P guidance: The concomitant use of alprazolam with CYP3A4 inhibitors may result in increased alprazo prolonged sedation. Impairment of motor skills are also observed with some combinations. Monitor p exaggerated sedative effects. If possible, alprazolam should be avoided in patients receiving strong in CYP3A4 such as ketoconazole, itraconazole and ritonavir. Drugs that induce CYP3A enzymes may decipitate alprazolam levels, which results in a loss of efficacy.	Polypharmacy lam levels and patients for hibitors of
§√	Zofran	Normal Response to Ondansetron (CYP2D6: Normal Metabolizer)	ACTIONABLE
Α 🖤	Ondansetron	Ondansetron can be prescribed at standard label-recommended dosage and administration.	
₹√	Zofran	Favorable Response to Standard Ondansetron Dosing (ABCB1: Homozygous Mutant - Variant Allele Present)	INFORMATIVE
	Ondansetron	The genotype result predicts that the patient has low ABCB1 transporter expression. Ondansetron car at standard label-recommended dosage and administration.	be prescribed
0 ⊗	Zofran & Lexapro	The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.	SERIOUS
	Zofran &		SERIOUS
• •	Citalopram		




SCENE	CVC	PATIENT INFORMATION	SPECIMEN DETAILS	;	ORDERED BY
GENE		NAME: John Doe ACC #: BS7 DOB: 12/24/1800 SEX: Male	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	Buccal Swab 1/1/1900 1/1/1900 8/26/2019	Dr. Bauer
	lead to higher p prolongation co with a greater ris abnormalities pr factors for QT pr should be perfor injection has spe or equal to 75 ye infused over at l	prolongation due to ondansetron eak concentrations and systemic mpared with the same dose give sk for QT prolongation. If concom ior to starting therapy. Monitor of rolongation (e.g. cardiac disease, rmed in patients receiving concur ecific recommendations for use o ears of age :- all IV doses must be east 15 minutes- initial and repea- ular heartbeat, dizziness, or fainting	exposure and so have a n orally. Faster rates of nitant therapy is needed closely, particularly in pa female, elderly). Electro rrent therapy.The Canad f IV ondansetron in ond e diluted in 50 - 100 mL at IV doses must not ex	a greater risk f IV infusion are d, correct elect atients with pr icardiogram (E dian manufact cology patients of compatible	or QT e also associated trolyte edisposing risk ECG) monitoring urer of Zofran s greater than e fluid and
🕞 🚫 Citalopram & Lexapro	recommends EC receiving concur discontinued in serum calcium, r	with agents known to prolong the G monitoring in patients for who rrent therapy with agents known patients with persistent QTc mea nagnesium, and potassium levels istruct patients to report any irreg	om citalopram is not rec to prolong the QT inter surements greater than at regular intervals. Co	ommended, ir val. Citaloprar 500 ms. Cons prrect any elec	ncluding those n should be sider obtaining trolyte
Unrecognized Medications: None					
monitoring; alternative therapy	may be needed. dicated condition or	rse drug reaction. Medication car adverse drug reaction. Medicatic		th A	
Typical risk for indicated condition standard dosing guidelines.	ion or adverse drug	reaction. Medication can be pres	scribed according to		RUG-DRUG INTERACTIONS
		nplementation in a clinical setting etic consortia, professional socie			5

INFORMATIVE Recommendations are informative and implementation in a clinical setting is optional. The evidence documenting these drug-gene associations may be limited or insufficient and may require further investigation. There are no established evidence based guidelines issued by international pharmacogenetic consortia, professional societies or regulatory bodies.

MODERATE Drug interactions of moderate severity. The clinician should assess the patient's characteristics and take action as needed.

Serious Severe drug interaction or contraindicated drug combination which may produces serious consequences in most patients. This drug combination generally should not be dispensed or administered to the same patient. Action is required to reduce risk of severe adverse interaction.







Lab Director: Frank A. Bauer MD | CLIA: 07D2046796 | CT CL-0687 | 8 Enterprise Lane, Oakdale, CT 06370 | www.gdilabs.com | (860) 574-9172



PATI	ENT	INFO	DRM	ATIC

NAME: John Doe ACC #: BS7 DOB: 12/24/1800 SEX: Male

SPECIMEN DETAILS

COLLECTION DATE: 1/1/1900

SPECIMEN TYPE:

RECEIVED DATE:

REPORT DATE:

ORDERED BY

Dr. Bauer

Buccal Swab

1/1/1900

8/26/2019

🕂 Zofran & Alfuzosin

The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.

🕂 Zofran & Asenapine

The US manufacturer of asenapine states that the concurrent administration of other drugs that are known to prolong the QTc interval should be avoided.If concurrent therapy is warranted, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting.

🕂 Zofran & Atomoxetine

The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.

🗙 Zofran & Chlorpromazine

The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.

🗙 Zofran & Citalopram

The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.

<u>/ Zofran & Clomipramine</u>

MODERATE

The risk for QT prolongation due to ondansetron is dose and route related. Intravenous (IV) doses lead to higher peak concentrations and systemic exposure and so have a greater risk for QT prolongation compared with the same dose given orally. Faster rates of IV infusion are also associated with a greater risk for QT prolongation. If concomitant therapy is needed, correct electrolyte abnormalities prior to starting therapy. Monitor closely, particularly in patients with predisposing risk factors for QT prolongation (e.g. cardiac disease, female, elderly). Electrocardiogram (ECG) monitoring should be performed in patients receiving concurrent therapy. The Canadian manufacturer of Zofran injection has specific recommendations for use of IV ondansetron in oncology patients greater than or equal to 75 years of age :- all IV doses must be diluted in 50 - 100 mL of compatible fluid and infused over at least 15 minutes- initial and repeat IV doses must not exceed 8 mg.Instruct patients to report any irregular heartbeat, dizziness, or fainting.



MODERATE

MODERATE

MODERATE

SERIOUS

SERIOUS